These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 30527443

  • 1. New Insights into the Regulation of CGRP-Family Receptors.
    Gingell JJ, Hendrikse ER, Hay DL.
    Trends Pharmacol Sci; 2019 Jan; 40(1):71-83. PubMed ID: 30527443
    [Abstract] [Full Text] [Related]

  • 2. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
    Mullin K, Kudrow D, Croop R, Lovegren M, Conway CM, Coric V, Lipton RB.
    Neurology; 2020 May 19; 94(20):e2121-e2125. PubMed ID: 31932515
    [Abstract] [Full Text] [Related]

  • 3. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K, Michael RL, Rapoport AM.
    Drugs; 2018 Jun 19; 78(9):913-928. PubMed ID: 29869205
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC, Schwedt TJ.
    Prog Brain Res; 2020 Jun 19; 255():143-170. PubMed ID: 33008505
    [Abstract] [Full Text] [Related]

  • 8. Eptinezumab: First Approval.
    Dhillon S.
    Drugs; 2020 May 19; 80(7):733-739. PubMed ID: 32266704
    [Abstract] [Full Text] [Related]

  • 9. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
    Edvinsson L, Haanes KA, Warfvinge K, Krause DN.
    Nat Rev Neurol; 2018 Jun 19; 14(6):338-350. PubMed ID: 29691490
    [Abstract] [Full Text] [Related]

  • 10. Erenumab: First Global Approval.
    Markham A.
    Drugs; 2018 Jul 19; 78(11):1157-1161. PubMed ID: 29968151
    [Abstract] [Full Text] [Related]

  • 11. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R, Olesen J.
    Headache; 2019 Jun 19; 59(6):951-970. PubMed ID: 31020659
    [Abstract] [Full Text] [Related]

  • 12. Erenumab in the treatment of migraine.
    Jain S, Yuan H, Spare N, Silberstein SD.
    Pain Manag; 2018 Nov 01; 8(6):415-426. PubMed ID: 30235976
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antigens and Antibodies in Disease With Specifics About CGRP Immunology.
    Taylor FR.
    Headache; 2018 Nov 01; 58 Suppl 3():230-237. PubMed ID: 30187471
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system.
    Chen ST, Wu JW.
    Prog Brain Res; 2020 Nov 01; 255():123-142. PubMed ID: 33008504
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
    Dodick DW.
    Cephalalgia; 2019 Mar 01; 39(3):445-458. PubMed ID: 30661365
    [Abstract] [Full Text] [Related]

  • 20. CGRP/CGRP Receptor Antibodies: Potential Adverse Effects Due to Blockade of Neovascularization?
    Majima M, Ito Y, Hosono K, Amano H.
    Trends Pharmacol Sci; 2019 Jan 01; 40(1):11-21. PubMed ID: 30502971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.